Value in Health
Vol 16 | No. 5 | July-August 2013 | Pages 699-906
Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey
Özden Türel, MD, Adnan Kisa, MSPH, PhD, E. David G. McIntosh, MBBS, MPH, LLM, PhD, ,
Mustafa Bakir, MD
Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain “standard of care” if not improve it, and that it could be affordable.
Objectives and Methods
The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a “no vaccine” state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon.
Results and Conclusions
The cost per life-year gained is below the 1 × per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.